Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis (Q56829837)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Walter E Haefeli

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Jürgen Burhenne

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

E Ngaimisi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

S Mugusi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

O Minzi

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

P Sasi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

K-D Riedel

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A Suda

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

N Ueda

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Janabi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F Mugusi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

L Bertilsson

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

0 references

publication date

3 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

90

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

406-413

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21814190%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

https://scigraph.springernature.com/pub.10.1038/clpt.2011.129

0 references

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Causes of death in HIV-infected persons who have tuberculosis, Thailand

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

21 January 2018

Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.129

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56829837&oldid=1982918787"